UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039937
Receipt number R000045486
Scientific Title Evaluation of the safety and efficacy of continuous use of skincare formulations
Date of disclosure of the study information 2020/03/25
Last modified on 2020/09/24 08:33:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the safety and efficacy of
continuous use of skincare formulations

Acronym

Evaluation of the safety and efficacy of
continuous use of skincare formulations

Scientific Title

Evaluation of the safety and efficacy of
continuous use of skincare formulations

Scientific Title:Acronym

Evaluation of the safety and efficacy of
continuous use of skincare formulations

Region

Japan


Condition

Condition

Healthy

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the safety and efficacy of the continuous use of moisturizing agents in subjects with facial dryness

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) Evaluation of improvement in cutaneous findings and dryness/scaly skin
2) Frequency of side effects

Key secondary outcomes

Instrumental measurements
1) Water content of stratum corneum
2) Transepidermal water loss


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

The test product is applied to the entire face twice a day (morning and evening).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Female

Key inclusion criteria

People who meet inclusion criteria 1) to 7) listed below and meet none of the exclusion criteria will be enrolled in the increasing order of the measured moisture content in the stratum corneum, with a target of 44 subjects with the lowest moisture content in the stratum corneum.
Inclusion criteria:
1) Subjects who were willing to participate in the study and, after receiving an explanation of the study, who provided voluntary consent to participate in the study.
2) Healthy Japanese women aged between 20 years and less than 60 years who meet none of the exclusion criteria
3) Subjects who can complete documents such as a consent form and journal form
4) Subjects who can provide responses to an Internet-based questionnaire
5) Subjects who can visit the designated facility on the day of measurement
6) Subjects who have slight-to-mild facial dryness and scaly skin on the face or have a history of atopic dermatitis, which is in remission at the time of screening, and have facial dryness.
7) Self-perception of having sensitive skin

Key exclusion criteria

1)Subjects who have a facial injury
2)Those who used a medicinal product that can potentially affect the study within 3 months of the start of the study or who will probably use a drug that can potentially affect the results during the study period
3)Subjects who underwent a cosmetic procedure such as collagen or hyaluronic acid injection, botox injection, chemical peeling, laser therapy, or phototherapy within 6 months of the start of the study or who will probably undergo one of the above-mentioned cosmetic procedures during the study period
4)Those currently receiving hormone replacement therapy or who will probably receive hormone replacement therapy during the study period
5)Those who will probably experience substantial exposure to sunlight during the study
6)Those who have previously developed serious skin problems arising from the use of cosmetic products or other similar products
7)Those who have previously developed
dermatitis due to adhesive tape or other similar products
8)Subjects whose face is affected by atopic dermatitis or another skin disease
9)Those who suffer from severe hay fever
10)Those who habitually consume excess amounts of alcohol
11)Those who are unable to discontinue drugs that can potentially affect the study results
12)Those who have a history of severe liver disease, kidney disease, myocardial infarction, or other similar serious conditions and who will probably start to receive a new treatment at a medical institution during the study period
13)Those who suffer from severe anemia
14)Those who are pregnant or will potentially become pregnant during the study or who are breast-feeding
15)Those who will have participated in another clinical study between 3 months before screening and the end of this study or will probably participate in another clinical study during this study period
16)Subjects whose enrollment in the study is considered inappropriate by the principal investigator

Target sample size

44


Research contact person

Name of lead principal investigator

1st name Yuko
Middle name
Last name Tsukamoto

Organization

Beauty & Health Research Inc.

Division name

Clinical Research Division

Zip code

160-0023

Address

4th Floor, Sankyo Nishi-Shinjuku Bldg., 4-2-18 Nishi-Shinjuku, Shinjuku-ku, Tokyo

TEL

03-5354-7388

Email

info@b-hr.jp


Public contact

Name of contact person

1st name Ai
Middle name
Last name Marume

Organization

Beauty & Health Research Inc.

Division name

Clinical Research Division

Zip code

160-0023

Address

4th Floor, Sankyo Nishi-Shinjuku Bldg., 4-2-18 Nishi-Shinjuku, Shinjuku-ku, Tokyo

TEL

03-5354-7388

Homepage URL


Email

marume@b-hr.jp


Sponsor or person

Institute

Beauty & Health Research Inc.

Institute

Department

Personal name



Funding Source

Organization

KOSE Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hakuaikai G.K.

Address

3-10-2 Higashiazabu, Minato-ku, Tokyo

Tel

03-5354-7388

Email

hakuaikai.rinri@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

株式会社ビューティアンドヘルスリサーチ


Other administrative information

Date of disclosure of the study information

2020 Year 03 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

46

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 11 Month 10 Day

Date of IRB

2019 Year 11 Month 11 Day

Anticipated trial start date

2020 Year 01 Month 10 Day

Last follow-up date

2020 Year 04 Month 27 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 03 Month 25 Day

Last modified on

2020 Year 09 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045486


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name